Conflict of interest: Nothing to report
Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma†
Article first published online: 26 MAY 2010
Copyright © 2010 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 55, Issue 6, pages 1217–1220, 1 December 2010
How to Cite
Walsh, A., Kelly, D. R., Vaid, Y. N., Hilliard, L. M. and Friedman, G. K. (2010), Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr. Blood Cancer, 55: 1217–1220. doi: 10.1002/pbc.22611
- Issue published online: 25 OCT 2010
- Article first published online: 26 MAY 2010
- Manuscript Accepted: 5 APR 2010
- Manuscript Received: 5 MAR 2010
- renal medullary carcinoma
Renal medullary carcinoma (RMC) is a rare and aggressive malignancy seen primarily in patients with sickle-cell trait. We report a complete response to carboplatin, paclitaxel, and gemcitabine in a patient with advanced metastatic RMC. Pediatr Blood Cancer. 2010;55:1217–1220. © 2010 Wiley-Liss, Inc.